(b)(4).The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.Additionally, a review of the complaint history identified no other complaints reported from this lot.It should be noted that the supera instruction for use (ifu) states: ¿under fluoroscopy, remove the device from the guide wire and evaluate the improved luminal quality of the treated area.¿ although the device was removed without fluoroscopy, this did not cause the deployment issue of the stent not fully releasing.Based on the information provided, a conclusive cause for the reported difficulty could not be determined.It is possible that the distal sheath of the supera delivery system was bent or angled in the anatomy such that the ratchet was unable to engage the stent properly preventing full deployment; however, this could not be confirmed.There is no indication of a product quality issue with respect to the design, manufacture, or labeling of the device.
|
It was reported that the procedure was to treat the 5.0 mm, non tortuous, mildly calcified right superficial femoral artery (sfa).Atherectomy was performed and the lesion was pre-dilated with a non-abbott 5.0x100 mm balloon.The supera self expanding stent (ses) was advanced and believed to be fully deployed.The delivery system was not removed under fluoroscopy and when it was removed, it was found that the stent was only partially deployed and had been removed with the sheath.An absolute pro ses was deployed to complete the procedure.There were no adverse patient effects and there was no clinically significant delay in the procedure.No additional information was provided.
|